There are few conditions that have more significance for rational practice and neurologic science than does Parkinson's disease (PD), and PD remains in the forefront in discussions of abiotrophy and degeneration, dementia and cognition, animal models and receptors, and genetic and environmental causation, as well as in the discussion of protective, symptomatic, and surgical therapy. One apparent advance since levodopa revolutionized therapy is special interest in movement disorders by many neurologists. Most general neurologists are now skilled at, or at least fascinated by, disorders of movement. Neurologists may feel not just adequately informed but actually bombarded by clinical reports, pharmaceutically sponsored symposia, and definitive experts. Nevertheless, puzzles in the diagnosis of PD, uncertainty in choice of therapy, unsatisfactory results of long-term management, and end-stage despair remain common experiences for us all. What drug to start, what to avoid, what to combine, and how to follow up the patient are not
Paulson GW. Therapy of Patients With Parkinson's Disease. Arch Neurol. 1994;51(8):754–756. doi:10.1001/archneur.1994.00540200028012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.